Difference in Quantities of Bifidobacteria from the Intestinal Microflora of Individuals with Type 2 Diabetes and Healthy Individuals from Iran

Document Type : Original Article (s)

Authors

1 Faculty Member, Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

2 Professor, Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Obesity and Diabetes are two metabolic diseases that are dependent on genetic and various environmental factors. Today, obesity and type 2 diabetes cannot just be attributed to genome changes, bad eating habits, or physical activity reduction. Gut microflora is another effective factor that has an important role in health. Recently, numerous experiments have been done to investigate the relation between metabolic diseases and bacterial populations in the gut. The purpose of this study is to assess the bifidobacteria of the intestinal microbiota in people with type 2 diabetes and compare with healthy persons.Methods: In this study, 40 male and female adults, 20 of whom were diagnosed with type 2 diabetes, were studied. For this study, age, gender, and body-mass index (BMI) are matched in diabetic and healthy persons. After fecal sample collection from diabetic and healthy persons, and extraction of DNA from samples, culture and extraction of DNA from standard bifidobacteria were done as a positive control. After that, cloning in PTZ57 R/T plasmid and extraction cloning plasmid was done. For quantitative investigation of bifidobacteria, Real-time PCR molecular technique was done by using special primer of bifidobacterium and standard curve. To study the number of bifidobacteria in people with type 2 diabetes and compare with healthy persons, statistical analysis was done.Findings: Average number of bacteria in people with type 2 diabetes is more than in healthy persons, but Student’s independent t-test) P = 0.09) and Mann-Whitney test (P = 0.1) indicate that there are no meaningful differences between them.Conclusion: Quantitative calculation with Real-time PCR indicates that the number of bifidobacteria is not effective in Iranian type 2 diabetes patients. 

Keywords

References

  1. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5(2): e9085.
  2. An HM, Park SY, Lee dK, Kim JR, Cha MK, Lee SW, et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 2011; 10: 116.
  3. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; 5(8): e12191.
  4. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53(4): 606-13.
  5. Shahshan T, Karimi J. Prevention of type 2 diabetes mellitus. Chaharbagh Publication: Isfahan, Iran: 2002. p. 56-98.
  6. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris) 2008; 56(5): 305-9.
  7. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One 2009; 4(9): e7125.
  8. Pataky Z, Bobbioni-Harsch E, Hadengue A, Carpentier A, Golay A. Gut microbiota, responsible for our body weight?. Rev Med Suisse 2009; 5(196): 662-4, 666.
  9. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56(7): 1761-72.
  10. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83(4): 460-9.
  11. Huys G, D'Haene K, Danielsen M, Matto J, Egervarn M, Vandamme P. Phenotypic and molecular assessment of antimicrobial resistance in Lactobacillus paracasei strains of food origin. J Food Prot 2008; 71(2): 339-44.
  12. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 2000; 66(5): 2263-6.
  13. Stsepetova JE. The characterisation of intestinal lactic acid bacteria using bacteriological, biochemical and molecular approaches [Thesis]. Tartu, Estonia: University of Tartu; 2011. p. 234-51.
  14. Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr 2013; 12: 1-16. [Epub ahead of print]
  15. Barengolts E. Vitamin D and Prebiotics May Benefit the Intestinal Microbacteria and Improve Glucose Homeostasis in Prediabetes and Type 2 Diabetes. Endocr Pract 2013; 1-40.
  16. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14(2): 112-20.
  17. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87(3): 534-8.
  18. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009; 9(6): 737-43.
  19. Wang X, Wen Sh, Li H, Yuan J. Effect of Lactobacillus acidophilus on the prevention and treatment of type II diabetes in mice. Chinese Journal of Microecology 2010; 22(12): 1069-73.
  20. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004; 47(3): 357-66.
  21. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50(11): 2374-83.
  22. Mai V, Draganov PV. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol 2009; 15(1): 81-5.
  23. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22(7): 2416-26.
  24. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26(1): 5-11.
  25. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 2010; 104(12): 1831-8.
  26. Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 2009; 107(5): 1681-6.
  27. Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010; 61(1): 69-78.
  28. Weickert MO, Arafat AM, Blaut M, Alpert C, Becker N, Leupelt V, et al. Changes in dominant groups of the gut microbiota do not explain cereal-fiber induced improvement of whole-body insulin sensitivity. Nutr Metab (Lond) 2011; 8: 90.
Journal of Isfahan Medical School
Volume 31, Issue 247 - Serial Number 247
July and August 2013
Pages 1216-1225

Files

History

  • Receive Date: 06 June 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics